EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Assessing kidney function for drug dosing in critical illness

Ming-Shen Lin iD, Kuo-Fan Liao iD

British Journal of Clinical Pharmacology · 06.11.2026

DOI: 10.1002/bcp.70911 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 06.11.2026. Verfasst von Ming-Shen Lin und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Far Eastern Memorial Hospital, New Taipei City, Taiwan. Die Arbeit nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kidney‐function assessment supports drug dosing in critical illness but does not directly measure drug clearance. Reduced creatinine generation, fluid shifts and rapidly changing filtration can make creatinine‐based estimates misleading, whereas genuinely augmented renal clearance can cause insufficient drug exposure. These processes can coexist. This narrative review distinguishes estimated glomerular filtration rate from estimated or measured creatinine clearance and explains how equation version, body‐surface‐area indexing and sampling time affect interpretation. It separates the 2021 creatinine, 2012 cystatin C and 2021 creatinine–cystatin C equations of the Chronic Kidney Disease Epidemiology Collaboration (CKD‐EPI) and considers when each can inform a clinical decision. Cystatin C provides complementary information, not an intensive‐care reference standard; timed urinary creatinine clearance is also vulnerable to collection error and changing physiology. We present a resource‐adapted assessment framework rather than a validated dosing algorithm. It accommodates delayed cystatin C results, unavailable or unreliable urine collections, non‐steady‐state kidney function and access to therapeutic drug monitoring. Augmented renal clearance is treated as a continuum, with drug‐specific thresholds distinguished from research definitions. Examples involving antibiotics, levetiracetam and gabapentin show why a kidney‐function estimate must match the metric used in the relevant label or pharmacokinetic model. The practical objective is a documented, revisable dosing decision that integrates estimated kidney function, drug exposure and the consequences of under‐ or over‐treatment, without assuming that biomarker discordance identifies its own cause.

Schlagwörter

Stichwörter der Autor:innen

augmented renalclearancecreatininecritical illnesscystatin Cdrug dosingglomerular filtrationratetherapeutic drugmonitoring

Autor:innen und Institutionen

  • Department of Pharmacy, Far Eastern Memorial Hospital, New Taipei City, Taiwan.
  • Department of Traditional Chinese Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan.
  • Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
  • Department of Nutrition and Health Sciences, Kainan University, Taoyuan City, Taiwan.

ORCID-Profile: Ming-Shen Lin, Kuo-Fan Liao

Zitieren

APA

Lin, M. S., & Liao, K. F. (2026). Assessing kidney function for drug dosing in critical illness. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70911

Vancouver

Lin MS, Liao KF. Assessing kidney function for drug dosing in critical illness. British Journal of Clinical Pharmacology. 2026. doi:10.1002/bcp.70911

BibTeX
@article{Lin2026,
  author = {Lin, Ming-Shen and Liao, Kuo-Fan},
  title = {Assessing kidney function for drug dosing in critical illness},
  journal = {British Journal of Clinical Pharmacology},
  year = {2026},
  doi = {10.1002/bcp.70911}
}
Kostenlos starten →